Allergy

The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

Psychology referrals for children with food allergies surged 11-fold in the last decade, but many still face limited access to therapy services due to geographic barriers.

Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.

Incorporating baked milk products into a regular diet may improve growth and quality of life in milk-allergic children.

This review compares the clinical and real-world outcomes of drugs such as mepolizumab versus drugs such as benralizumab for severe eosinophilic asthma.

A study found infants under 1 year with food allergies can safely consume small doses of allergens, which helps reduce allergic reactions later in life.

Data show age may be a significant effect on results from contact dermatitis patch tests.

Patients who underwent FESS required less medication and had fewer allergy and pulmonology visits than patients who did not have surgery.

Early epinephrine intervention at home can potentially successfully treat anaphylaxis in children without further treatment in a hospital setting.

This review provides an overview of current data on immune development and risk factors for preterm-born infant development of respiratory infections and wheezing.

A new study identified 9 distinct trajectories of asthma and allergy in children, with variations in disease progression, parental reporting, and medication use.

The literature review suggests allergen immunotherapy can effectively treat allergic asthma and prevent its development in patients with allergic rhinitis.

This research letter suggests that direct GOC may be considered efficacious for pediatric patients reporting non-severe symptoms which are skin-limited during a macrolide treatment.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

These findings highlight the underrepresentation of Black and Hispanic food allergy clinical trial participants and raise concerns about the generalizability of clinical research findings.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

Individuals with comorbid asthma and food allergies saw no loss of efficacy in this post hoc analysis, suggesting omalizumab’s potential for such patients.

The announcement follows July’s approval of the nasal spray, also known as neffy, for patients with Type 1 allergic reactions such as anaphylaxis.

People living with HP generally experience a profound lack of knowledge about their disease, driving poorer health-related quality of life. A study sought to create educational resources to curb this effect.

This approval expands the drug’s age range and follows recent positive phase 3 findings on dupilumab treatment for patients aged 12 to 17 with CRSwNP.

These real-world findings highlight the benefits of sustained dupilumab therapy for individuals with chronic rhinosinusitis with nasal polyps.

The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.

This analysis evaluated the long-term follow-up and risks linked to the self-reported penicillin allergy persistence after a successful oral penicillin challenge and allergy label removal.